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Objective: to test the hypothesis that the presence of Chlamydia pneumoniae (C. pneumoniae) in the wall of abdominal
aortic aneurysms (AAA) is associated with increased activity of matrix metalloproteinase (MMP)-2 and/or MMP-9.
Design: case±control study.
Material and Methods: in a series of 40 patients with AAA  5 cm in maximal cross-sectional diameter, C. pneumoniae-
DNA was identified in the aneurysm wall by nested PCR in 14 (35%) patients. Another 14 C. pneumoniae-
DNA-negative AAA patients from the same series, matched for gender and aneurysm diameter, were used as controls. In
each group there were 7 asymptomatic (aAAA) and 7 ruptured (rAAA) aneurysms. MMP-2 and -9 activity was estimated
in AAA wall biopsies by gelatin zymography.
Results: patients with a C. pneumoniae-DNA-positive aneurysm wall specimen showed an over-all lower activity of
MMP-2 and MMP-9 (pro- and active enzyme) compared to the C. pneumoniae-DNA negative patients. However, there
were no statistically significant differences in MMP activity between the two groups of patients with aAAA.
Among patients with rAAA both pro-MMP-9 (p 0,026) and active-MMP-9 (p 0.007) were significantly lower in
C. pneumoniae-DNA-positive patients compared to C. pneumoniae-DNA-negative patients, whereas there were no
significant differences in pro-MMP-2 or active-MMP-2.
Conclusion: this preliminary study does not support the hypothesis that the presence of C. pneumoniae in the AAA wall
is associated with increased activity of MMP-2 and MMP-9.
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Several studies have demonstrated the obligate intra-
cellular bacterium Chlamydia pneumoniae (C. pneumo-
niae) in the wall of up to half of all abdominal aortic
aneurysms (AAA).1±5 The bacterium may just be an
`` innocent bystander''. However, there are some indi-
cations suggesting an active role as there is a high
prevalence of C. pneumoniae seropositivity in patients
with AAA,4 and there seems to be an association
between serological evidence of C. pneumoniae infec-
tion and expansion of small AAA.6 C. pneumoniae
antigens stimulate aortic dilatation in an experimental
model,7 and C. pneumoniae reactive T-lymphocytes
have been identified in AAA.8 Furthermore it has
been shown that the presence of C. pneumoniae is asso-
ciated with increased degradation of elastin in aortic
tissue in vitro.9 Elastin degradation is considered a
primary event in AAA development.10 C. pneumoniae
is able to induce an inflammatory response in infectedPlease address all correspondence to: E. Petersen, Department of
Surgery, UmeaÊ University Hospital, 901 85 UmeaÊ, Sweden.
1078±5884/02/040365  05 $35.00/0 # 2002 Elsevier Science Ltd. Atissues11 and stimulate production of matrix metallo-
proteinase (MMP)-2 and MMP-9 by macrophages via
C. pneumoniae heat shock protein 60.12,13 As MMP-2
and MMP-9 are important factors involved in the
degradation of the extracellular matrix of the aortic
wall in AAA disease, it may be expected that the
presence of C. pneumoniae in AAA is associated with
increased activity of these MMPs.
The aim of this study was to test the hypothesis that
the presence of C. pneumoniae in the AAA wall is
associated with increased activity of MMP-2 and/or
MMP-9.
Materials
In a series of 40 consecutive patients operated
on for an AAA  5 cm in cross-sectional diameter,
C. pneumoniae-DNA was detected in the aneurysm
wall by nested polymerase chain reaction (PCR) in
14 (35%) of the patients.4 Seven of the C. pneumoniae-
DNA-positive patients had an asymptomatic AAA
(aAAA), whereas 7 had a ruptured AAA (rAAA).
C. pneumoniae-DNA-negative patients in the samell rights reserved.
Table 1. Patient characteristics.
aAAA rAAA
C. pneumoniae
DNA positive n 7
C. pneumoniae
DNA negative n 7
C. pneumoniae
DNA positive n 7
C. pneumoniae
DNA negative n 7
Age (years) 69 71 68 74
median, range (57±81) (64±80) (53±84) (58±79)
Gender F/M 1/6 1/6 1/6 1/6
AAA diameter (cm) 7 7 6 6
(median, range) (5±10) (5±10) (5±8) (5±8)
Diabetes 2 0 1 1
Hypertension 2 3 3 2
Smoking 1 1 3 2
aAAA: asymptomatic AAA; rAAA: ruptured AAA; F/M: Female/Male.
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as controls, matching the study groups with respect to
gender and AAA diameter. None of the patients were
treated with anti-chlamydial or metalloproteinase
inhibiting drugs before surgery. Patient characteristics
are presented in Table 1.
The maximal cross-sectional diameter of the aneur-
ysms was determined by preoperative ultrasono-
graphy and/or computed tomography scanning.
Full-thickness specimens from the central part of the
anterior aneurysm wall were collected from all
patients during surgery. The specimens were cleaned
of blood and dissected from associated fat, connective
tissue and mural thrombus. The specimens were
immediately stored at ÿ70C until analysis. Each spe-
cimen was divided in two: one for nested PCR and
the other for gelatin zymography. The study was
approved by the Scientific Ethical Committee, UmeaÊ
University Hospital and reported to the Central Con-
trol of Registers. All patients gave informed consent.
Methods
Nested PCR
Full thickness AAA wall specimens of approximately
25 mg each were analysed. The frozen tissues were
thawed on ice and cut into small pieces under sterile
conditions. DNA was purified using the QIAamp Tis-
sue kit (QIAGEN GmbH, Hilden, Germany). A part
of the major outer membrane protein gene (MOMP) of
C. pneumoniae was chosen as the target for amplifica-
tion in a nested touchdown PCR.4
The PCR method used in this study has been exten-
sively validated against other diagnostic methods
including cell culture, and found to be highly sensitive
and specific for the detection of C. pneumoniae.14 In
addition, a meeting was recently convened by the
Centres for Disease Control and Prevention (Atlanta,Eur J Vasc Endovasc Surg Vol 24, October 2002Georgia, U.S.A.) and the Laboratory Centre for
Disease Control (Ottawa, Ontario, Canada) to review
current diagnostic tests for C. pneumoniae and provide
recommendations for standardised approaches. Out
of 18 PCR assays described in published reports,
four assays, including the assay used in our study,
met the proposed validation criteria.15
Extraction of MMP-2 and MMP-9
MMP were extracted from full-thickness AAA speci-
men of approximately 2 g (wet weight).16 The speci-
mens were crushed to powder under liquid nitrogen
and extracted three times by vigorous shaking with 10
volumes of 10 mM Tris (pH 7.5), 5 mM EDTA, 0.2 M
NaCl and 2 mM phenyl methylsulphonylfluoride
(PMSF) for 12 h. In the third extract we found only
traces of protein and negligible expressions of MMP-2
and MMP-9. The first two extracts were combined,
centrifuged at 20 000 g for 30 min, and filtered milli-
pore 0.2 mm. Clear protein solutions were used for
zymography. The concentration of protein (mg/ml)
in each homogenate was measured.
Gelatin zymography
Gelatin zymography was performed on a 10% poly-
acrylamide gel slab (6 cm long, 0.75 mm thickness)
containing 0.3±0.6 mg/ml gelatin.16 The homogenates
were mixed 3:1 (vol/vol) with Laemmi sample solu-
tion. Equal amount of protein from each sample was
loaded on the gels. Electrophoresis was carried out at
4C for 2.5 h keeping the voltage constant at 140 V.
Following electrophoresis the gel was washed twice
for 30 min each, in 100 ml of 2.5% Triton X-100, rinsed
three times with water and once with 0.05 M Tris buf-
fer (pH 7.5), containing 0.005 M CaCl2 and 0.001 M
ZnCl2 in 0.01 M acetic acid. The gels were incubated
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sie brilliant blue G-250, the bands of MMP-9 (molecu-
lar mass 92 kDa (pro-enzyme) and 84 kDa (active
enzyme) and MMP-2 (molecular mass 72 kDa (pro-
enzyme) and 62 kDa (active enzyme) were identified
and the gelatinolytic activities were quantified by den-
sitometry using a 2020 Ultrascan Laser Densitometer
(LKB, Sweden). Electrophoresis of each sample was
performed twice and each lane on the zymogram was
scanned three times. The activities of MMP-2 and
MMP-2 (pro-and active enzyme) were calculated and
expressed in arbitrary units (au).
Statistics
The statistical program SPSS 11.0 and Mann±Whitney
U-test were used to test differences between the
groups. All values are given as median and range.
Statistical significance was set at p5 0.05.
Results
Patients with a positive C. pneumoniae-DNA test of the
aneurysm wall biopsy showed an over-all lower acti-
vity of MMP-2 and MMP-9 (pro- and active enzyme)
compared to the C. pneumoniae-DNA-negative patients.
However, there were no statistically significant differ-
ences in MMP activity between the two groups of
patients with aAAA. Among patients with rAAA,
both pro-MMP-9 (p 0.026) and active-MMP-9
(p 0.007) were significantly lower in C. pneumoniae-
DNA-positive patients compared to C. pneumoniae-
DNA-negative patients, whereas there were no
significant differences in pro-MMP-2 or active-
MMP-2 (Table 2).
Among C. pneumoniae-DNA-negative patients,
MMP-9 activity, but not MMP-2 was significantly
higher in rAAA compared to aAAA (p 0.04). No
difference in MMP activity was seen between aAAATable 2. Results.
aAAA
C. pneumoniae-
DNA-positive n 7
C. pneumoniae-
DNA-negative n 7
Pro-MMP-2 227 (116±1243) 512 (112±882)
Act-MMP-2 188 (59±677) 212 (100±625)
Pro-MMP-9 397 (325±1993) 617 (254±1429)
Act-MMP-9 209 (151±1043) 226 (71±577)
Au: arbitrary units; Pro-MMP; inactive matrix metalloproteinas
matic AAA; rAAA: ruptured AAA.and rAAA among C. pneumoniae-DNA positive
patients.
Discussion
The results of this preliminary study do not support
the hypothesis that the presence of C. pneumoniae in the
AAA wall is associated with increased activity of
MMP-2 and MMP-9. Actually, the over-all activity
of MMP-2 and MMP-9 was lower in AAA walls con-
taining C. pneumoniae.
We have presently reported that AAA rupture is
associated with increased activity of MMP-9 in the
AAA wall.16 In the present study the activity of
MMP-9 was relatively high in C. pneumoniae-
DNA-negative rAAA but significantly lower in
C. pneumoniae-DNA-positive rAAA. This suggests that
factors other than MMP-9 may contribute to matrix
degradation and rupture of C. pneumoniae-DNA-
positive AAA. Additionally, MMP-9 activity was, as
expected,6 significantly higher in rAAA than in
aAAA among C. pneumoniae-negative patients. How-
ever, this was not the case for C. pneumoniae-positive
patients. Although these groups were not matched
with respect to gender and aneurysm size, this
finding may also argue the case for a difference in
behaviour between C. pneumoniae-positive and nega-
tive AAA.
C. pneumoniae can replicate in endothelial cells,
smooth muscle cells and macrophages.17 Chlamydial
heat-shock proteins have been shown to activate these
cells, increasing the secretion of MMP.12,13 Therefore,
the type and number of cells, both inflammatory and
native mesenchymal cells, present in the AAA tissue,
may have important influence on the amount and
variety of proteinases released. C. pneumoniae-DNA-
positive AAA walls may have a different variety of i.e.
inflammatory cells compared to C. pneumoniae-DNA-
negative AAA, giving rise to a different proteinase
profile. Unfortunately there was not sufficient
material to examine the samples by histology.rAAA
p C. pneumoniae-
DNA-positive n 7
C. pneumoniae-
DNA-negative n 7
p
0.71 151 (63±1280) 731 (236±1255) 0.05
0.71 110 (45±618) 173 (77±784) 0.38
0.81 701 (294±1372) 1406 (508±1834) 0.03
0.81 158 (94±246) 300 (192±559) 0.01
e; Act-MMP: active matrix metalloproteinase; aAAA: asympto-
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nase similar to Chlamydia psittaci,18 which could
enable degradation of the extracellular matrix. In this
study we used a qualitative PCR , enabling us to
assess whether C. pneumoniae DNA was present or
not. By using a quantitative PCR, it might be possible
to estimate the load of C. pneumoniae bacteria in
the tissues. Infections with C. pneumoniae and other
Chlamydiae are known to cause intense inflammatory
reactions,19 and the number of C. pneumoniae bacteria
infecting the tissue may have an impact on the tissue
reaction. Using immunocytochemistry, we have found
that C. pneumoniae is scattered irregularly through
the aneurysm tissue, with spots of C. pneumoniae and
areas without C. pneumoniae. Some of the AAA might
therefore contain C. pneumoniae, although the small
analysed specimen was negative. This might have
affected our results.
Non-gelatinolytic proteinases, not identified by
gelatin zymography, may also contribute to matrix
degradation. In mycotic aneurysms the degenera-
tive enzymes are mainly serine and of neutrofile
origin.20,21 It is therefore possible that the tentative
proteinases in C. pneumoniae-DNA-positive AAA
are mainly of serine origin, whereas proteinases
in C. pneumoniae-DNA-negative AAA are mainly
metalloproteinases.
In a recent study it was claimed that antibodies
against C. pneumoniae predict the need for elective
intervention on small aneurysms.6 IgG antibodies
were most predictive for cases expanding to operation
recommendable sizes. In AAA disease, C. pneumoniae
infection, if present, is persistent or chronic, and the
current opinion is that neither elevated IgA titres nor
any other serologic markers are validated indicators of
persistent or chronic infection.22 Interpretation of ser-
ology and correlations to other parameters such as
expansion rate should therefore be interpreted with
caution. We have presently shown that there is a cor-
relation between expansion of larger AAA and
increasing MMP-2 levels.23 The present study does
not therefore support that AAA expansion in cases
of C. pneumoniae infection is mediated by MMP-2.
Although the present study does not find an asso-
ciation between C. pneumoniae and increased activity
of MMP-2 and MMP-9 in the AAA wall, it does not
exclude a role for C. pneumoniae in the development
and progression of AAA through other mechanisms.
C. pneumoniae may play a role in early AAA develop-
ment, while later being an `` innocent bystander''. The
possible elastolytic capacity of C. pneumoniae9 may
stimulate or accelerate the cascade of proteolytic
events leading to AAA development through the pro-
duction of elastin-derived peptides.Eur J Vasc Endovasc Surg Vol 24, October 2002In conclusion, the present study does not support
the hypothesis that the presence of C. pneumoniae in
the AAA wall is associated with increased activity of
MMP-2 and MMP-9.
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